Merck & Co. Buys Out OncoImmune For Phase III COVID-19 Therapy

 
• By Joseph Haas
Coronavirus with cardio lines, cellular designs and lungs
Merck & Co. likes therapeutic potential of OncoImmune's recombinant fusion protein

More from Deals

More from Business